GHK-Cu vs. melanotan II for skin aging: what the research says

What did @thepepphixofficial actually say?

The creator's core argument is straightforward: running Melanotan II (MT2) before GHK-Cu is a mistake for anyone targeting skin concerns like hyperpigmentation, dark spots, or melasma. They claim MT2 "increasing melanin production" can worsen those exact conditions, and that GHK-Cu, possibly paired with glutathione, is a smarter starting point. They frame this as advice aimed at the "19 year old looks maxing influencers" who don't yet have these skin concerns and therefore don't understand the tradeoff.

They also describe GHK-Cu as helping with "fine lines and wrinkles, dark hollow under eyes, hyperpigmentation and evening out the skin tone," and call glutathione a "master antioxidant" that is "incredible not just for detox but for brightening the skin."

The video ends with a call to book a consultation, which at least flags the commercial interest at play here.

Does the science back this up?

Mostly, yes, on the MT2 and melanin risk point. The GHK-Cu claims are supported but overstated in places. The glutathione claims are real but come with significant caveats about delivery method and evidence quality.

MT2 (melanotan II) is a synthetic analog of alpha-melanocyte-stimulating hormone. It binds melanocortin receptors and does increase melanin synthesis. That mechanism is real. What is also real is the documented risk of melanocytic changes. A 2009 case series published in the British Journal of Dermatology (Bowling et al.) reported new or changing moles in patients using MT2, including one case that required excision. The claim that MT2 can worsen existing hyperpigmentation is biologically plausible and consistent with how melanogenesis works, though direct clinical trials on MT2 and melasma specifically are limited.

GHK-Cu has a more legitimate research base than most peptides discussed in wellness content. Pickart and Margolina (2018, Cosmetics) reviewed evidence showing GHK-Cu promotes collagen synthesis, skin repair, and antioxidant gene expression. The hyperpigmentation angle is less studied than the wound-healing and collagen data, but there is some mechanistic support via GHK-Cu's effect on matrix metalloproteinases and skin remodeling.

Glutathione for skin brightening has evidence, but it's heavily route-dependent. Oral glutathione studies, including a randomized controlled trial by Arjinpathana and Asawanonda (2012, Journal of Dermatological Treatment), showed modest skin-lightening effects. Intravenous use is a different story with different risks. The creator doesn't specify route, which matters a lot clinically.

What did they get wrong (or right)?

They got the MT2 risk framing largely right, and credit is due for that. Warning people with existing hyperpigmentation or melasma away from a melanin-stimulating compound is responsible advice. The mechanism they describe is accurate.

Where they overreach is on GHK-Cu's scope. Saying it helps with "dark hollow under eyes" is a stretch. Under-eye hollowing is often structural, involving fat pad loss and bone resorption, neither of which a topical or systemic copper peptide is going to fix. The collagen-synthesis data does not translate cleanly into volume restoration under the eyes.

The glutathione framing is also sloppy. Calling it a "master antioxidant" and saying it's "incredible for detox" is wellness-speak that papers over the fact that glutathione's bioavailability when taken orally is genuinely contested. A 2015 randomized trial by Richie et al. (European Journal of Nutrition) found oral supplementation did raise blood glutathione levels, but translating that into meaningful skin brightening requires more evidence than the creator implies.

They also never mention that MT2 is not approved by the FDA for any indication, or that it carries more serious risks beyond skin changes, including nausea, spontaneous erections, and blood pressure changes documented in clinical pharmacology work by Wessells et al. (2000, Journal of Urology). That omission matters.

What should you actually know?

If you have melasma, post-inflammatory hyperpigmentation, or a history of atypical moles, MT2 is a compound worth being cautious about. That's not a fringe opinion, it follows directly from how the compound works. The creator is right to flag this, even if their framing is self-promotional.

GHK-Cu has a more credible evidence base than most peptides discussed in TikTok skincare content, but the evidence is still largely preclinical or small-scale. It is not a proven treatment for any skin disease, and the under-eye claim in particular should not be taken at face value.

Glutathione's skin effects are real but modest and highly dependent on how it's administered. Anyone considering intravenous glutathione specifically should have that conversation with a licensed clinician, not a TikTok founder.

Finally, the person in this video is promoting a skincare brand and a paid consultation service. That doesn't make them wrong, but it does mean you should apply the same skepticism you'd apply to any other branded health content. The science here is partially real. The confidence level in presenting it is higher than the evidence warrants.